Industries > Pharma > Global Asthma & COPD Therapies Market 2019-2029

Global Asthma & COPD Therapies Market 2019-2029

Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs

PUBLISHED: 19 March 2019
PAGES: 309
PRODUCT CODE: PHA0359
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1

The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period. In 2018, the combination drugs segment held 39% of the global asthma & COPD market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 309-page report you will receive 112 tables and 131 figures– all unavailable elsewhere.

The 309-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Asthma & COPD Therapies Market forecasts from 2019-2029, further broken down into:
Global Asthma Therapies Market forecasts
Global COPD Therapies Market forecasts

Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
• Bronchodilators monotherapy
• Anti-inflammatory drugs
• Combination drugs

Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
• Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
• Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
• Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
• Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
• Anti-leukotrienes: Singulair
• Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

Revenue forecast for the Combination drugs market and the leading drugs:
• Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2019-2029 for these regional and national markets:
• The US
• Japan
• EU5: Germany, France, UK, Italy, Spain
• BRIC: Brazil, Russia, India, China
• Mexico
• Other Countries

Global Asthma & COPD Therapies Market 2019-2029

• This report discusses the leading companies in the global asthma & COPD therapies market:
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.

Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Asthma & COPD Therapies Market Analysis : Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2019-2029


Latest Pharma news

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2021-2031

Increasing demand for medical products in developing as well developed economies coupled with rising ageing population is expected to open new opportunities for medical device contract manufacturing industry over the forecast period.

01 December 2020

READ

Visiongain Publishes Virus Testing Diagnostic Kits Market Report 2021-2031

With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries.

01 December 2020

READ

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020

READ

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

READ

Categories

Category